Combination therapy with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) is used to improve renal outcome achieved by monotherapy in diabetic patients. In addition, interference with the renin-angiotensin system (RAS) reduced expression and excretion of transforming growth factor β 1 (TGF-β 1 ) in diabetic nephropathy. The aim of this study was to investigate the effects of interrupting the RAS by ACE inhibitor (ACE-I) or ARB monotherapy or by combination therapy on proteinuria, kidney hypertrophy and plasma TGF-β 1 in diabetic rats.
Introduction
Blockade of the renin-angiotensin system (RAS) by angiotensin-converting enzyme (ACE) inhibitors or angiotensin II (Ang II) receptor blockers (ARBs) was found to be renoprotective in diabetes, both in humans [1] [2] [3] and in animal models. [4] [5] [6] Combination therapy with ACE inhibitors (ACE-Is) and ARBs was used in order to improve renal outcome compared to that obtained by monotherapy in diabetic patients. Results varied, with combination therapy being better, 7 or not different than monotherapy. 8 Both studies lasted only several weeks. A larger study which addressed this issue was also not conclusive. 9 Ang II may damage renal tissue by systemic and intraglomerular hypertension, but can also lead to chronic renal disease directly by stimulating transforming growth factor β 1 (TGF-β 1 ), a mediator of extracellular matrix deposition and fibrosis. 10 Ang II also stimulates aldosterone secretion, which may cause renal fibrosis independent of its hypertensive effect. 11 Indeed, interruption of the RAS has protective effects beyond that of reducing systemic blood pressure. 12 Elevated TGF-β 1 expression has been associated with pathological accumulation of extracellular matrix in the kidney in most animal models. 10 Yamamoto et al. found elevated TGF-β 1 in human and experimental diabetic nephropathy. 13 TGF-β 1 was proposed to mediate the effects of high glucose and Ang II on mesangial matrix metabolism in the diabetic rat. Recently, Hill et al. characterised the intrarenal TGF-β 1 system, including both mRNA and the peptide in the STZ-induced diabetic rat and in the biobreeding (BB) diabetic rat, and showed that the changes in the TGF-β 1 system resulted from the hyperglycaemic state. 14 Increased immunostaining for TGF-β 1 in the cortical tubulointerstitium and glomeruli and increased excretion of TGF-β 1 were observed in the untreated uninephrectomised diabetic rats. These were reduced by treatment with enalapril or losartan for 90 days. 15 Furthermore, treatment with an ARB reduced urinary TGF-β 1 in humans with diabetic nephropathy. 16 Treatment with anti-TGF-β 1 ‚ led to reduced proteinuria and renal structural pathology in streptozotocin (STZ) diabetic rats. 17 The aim of the present study was to investigate the effect of interrupting the RAS by ACE-I or ARB
monotherapy or combination therapy on proteinuria, kidney hypertrophy and plasma TGF-β 1 in diabetic rats.
Materials and methods

Experimental protocol
Experiments were performed on 225-240 g male Wistar rats (bred at Tel Aviv University, Israel).The experimental protocol was approved by the local committee for animal experimentation. Forty-one male Wistar rats were allocated to five groups: 1 = control rats (n=10), 2 = diabetic rats (diabetes was induced by a single injection of STZ into the tail vein at a dose of 55 mg/kg in 0.1 mL of citrate buffer, 0.1 mol/L, pH-4.5, n=10), 3 = diabetic rats as above receiving enalapril (20 mg/kg/day, n=7) 4 = diabetic rats as above receiving losartan (80 mg/kg/day, n=7) 5 = diabetic rats receiving both losartan and enalapril as above, n=7. The study lasted 60 days. Losartan was dissolved in tap water at different concentrations for each group, taking into account the water intake, in order to provide approximately equal amounts of losartan to each group. After 60 days, the rats were anaesthetised with chloral hydrate, blood was drawn for determination of creatinine, glucose, serum ACE activity and plasma TGF-β 1 and kidneys were removed. STZ-injected rats were considered diabetic if urinary sugar levels exceeded 5 g/L.The rats were divided into five groups and housed in individual metabolic cages prior to and 3, 30 and 59 days after STZ administration and 24-hour urine collections were obtained.
Blood samples for the determination of serum ACE activity and plasma TGF-β 1 were collected in plain tubes and tubes containing EDTA, respectively.
Biochemical determinations
Serum ACE activity was determined in all 41 rats prior to STZ injection. Serum ACE activity was assayed by a radiometric method described previously, 18 in which [ 3 H]-Hippuryl-glycyl-glycine was used as substrate. Serum samples were incubated with 800 nmol substrate (24,500 cpm, 234.6 µg) for 60 minutes at 37ºC in a final volume of 0.1 mL. Serum ACE activity was expressed as nmoles hip-puric acid released per minute per mL. Plasma TGF-β 1 was determined by ELISA after activation of latent TGF-β 1 to the immunoreactive form (R&D, Minneapolis, MN, USA) and expressed as pg/mL. Urinary protein was determined by the method of Bradford. 19 Creatinine in serum and urine was measured using a Beckman creatinine analyser (Beckman Instruments, Inc., Brea, USA).
Hippuryl-glycyl-glycine and STZ were obtained from Sigma (Holon, Israel). [ 3 H]-Hippuryl-glycylglycine (461 mCi/mmol) was purchased from Amersham (Buckinghamshire, UK).
Statistical analysis
Data are expressed as the mean±SD. Analysis of variance using the Duncan multiple comparison option was used for comparisons between groups. Linear regression analysis was performed by Pearson correlation. Two tailed p<0.05 was considered significant.
Results
Details on body weight, serum creatinine and blood and urinary glucose are given in Table 1 .The rats' body weight at baseline was similar in all groups except the combination treatment group, whose weight was slightly less than that of the controls. Control group weight increased progressively with time, whereas the weight of all four diabetic groups decreased significantly by 30 days (data not shown), and was maintained to the end of the study. However, while the weight of the enalapril-treated rats was similar to untreated diabetic rats, both losartan-treated groups, either as monotherapy or in combination with enalapril, lost significantly more weight than the untreated diabetic group (see Table 1 ). Urine volume in all diabetic groups increased by approximately 7-fold compared with controls (72.9±15.7 vs. 10.7±3.9 mL/24 hours). As shown in Table 1 , by 60 days serum creatinine was similar in all groups, blood glucose increased by 3-fold compared with controls and urinary glucose, which was undetected in the controls, was around 100 g/L in all diabetic groups. Results of protein excretion are given in Table 2 . Protein excretion was similar in all five experimental groups prior to induction of diabetes. By 30 days, protein excretion in the untreated 147 PAPER Table 1 Body weight (g), serum creatinine (mg/dL), blood glucose (mg/dL) and urinary glucose (g/L) at 60 days of treatment diabetic group almost doubled and remained at the same level to 60 days.Treatment with enalapril attenuated the proteinuria significantly by 60 days, but did not prevent it.Treatment with losartan completely inhibited the proteinuria at day 60. In contrast to the monotherapy with either drug, combination therapy completely suppressed proteinuria as early as 30 days. This effect was sustained to the end of the study. The kidney weights after 60 days of treatment are shown in Figure 1 . Kidney weight in the untreated diabetic group was 2.68±0.20 g, more than kidney weight in the control group (2.31±0.27 g). Kidney weights in the enalapril, losartan and combined groups were 2.37±0.28, 2.27±0.47, 2.16±0.24 g, respectively, significantly less than that of the untreated diabetic group and not different from the controls.
Plasma TGF-β 1 levels were significantly increased in the untreated diabetic group compared with the control group. Treatment with enalapril, losartan or both abolished the increased plasma TGF-β 1 (Figure 2 ). Plasma TGF-β 1 levels were positively correlated with blood glucose levels (r=0.4059, p<0.01) and with urinary protein excretion (r=0.3558, p<0.05).
Serum ACE activity remained almost constant in the control rats, but increased gradually with time in the untreated diabetic rats, being significantly increased by 22% and 50% after 30 and 60 days, respectively. Interestingly, losartan administration for 60 days, but not 30 days, abolished the increase in serum ACE activity seen in the untreated rats.ACE activity in the rats receiving enalapril was inhibited by more than 92% (Figure 3 ). Serum ACE activity was highly correlated with blood glucose levels in controls and untreated diabetic rats (r=0.8487, p<0.001, n=20). In vitro incubations of losartan (100 µg/incubation) with serum samples resulted in a 70% inhibition of ACE activity. Enalapril, at a concentration of 10 µg/incubation, resulted in a complete inhibition of ACE activity. In order to determine whether losartan has a chelating capacity, incubations were done in presence of 5 mM Ca ++ . The presence of Ca ++ did not affect the inhibitory effect of losartan (Table 3 ).
Discussion
This model of diabetes in adult rats presented with proteinuria, kidney hypertrophy and elevated plasma TGF-β 1 . Furthermore, the plasma TGF-β 1 level correlated with the 24-hour urinary protein excretion. Interruption of the RAS led to attenuation or complete prevention of proteinuria, renal hypertrophy and the rise in plasma TGF-β 1 .
Administration of enalapril attenuated the proteinuria, whereas administration of losartan for 60 days prevented proteinuria. The combination of losartan and enalapril treatment prevented proteinuria by 30 days and this effect was maintained to the end of the study. A similar pattern of the antiproteinuric effect of RAS interruption was observed in rats with 5/6 renal mass ablation. 20 The complete prevention of proteinuria by losartan with only partial inhibition of urinary protein excretion by enalapril could be related to a better abrogation of the RAS by AT 1 -receptor blockade with losartan, while inhibition by enalapril still allowed Ang II generation via non-ACE pathways. In addition, losartan prevented the rise in serum ACE activity observed in diabetic rats and reduced ACE activity, as shown in the in vitro study. It is suggested that losartan has a dual effect both on reducing ACE activity and blocking AT 1receptors, consequently being more effective than enalapril.
The early achievement of complete prevention of proteinuria by combined enalapril and losartan treatment is probably the result of a more effective interruption of the RAS within renal tissue compared to either monotherapy. 21 It may also be attributed to the increased treatment dose compared to that given to each of the monotherapy treatment groups. It is suggested that combination therapy leads to an earlier antiproteinuric effect in diabetic rats compared with monotherapy. This may be in accordance with the findings of Jacobsen et al., who described an additional reduction in albuminuria in Type 1 diabetic patients with dual RAS blockade by benazapril and valsartan 7 or enalapril and irbesartan, 22 compared with monotherapy with each of the drugs for eight weeks. In the present study, following a prolonged period of 60 days, losartan was as effective as the combination treatment in the diabetic rats.
Kidney hypertrophy after induction of diabetes is associated with an increase in urinary protein excretion. 23 Ang II is one of the growth factors involved in kidney hypertrophy in the diabetic rat. Ang II was shown to induce an increase in protein and DNA synthesis, as well as a hypertrophic response in rat mesangial cells. 24, 25 ACE-Is and ARBs were reported to reduce proteinuria and hypertrophy in human 26, 27 and experimental glomerular disease. 28, 20 In the present study, administration of enalapril, losartan or their combination prevented kidney hypertrophy in the diabetic rats. Recently, Itoh et al. reported that kidney weight in enalapril-treated diabetic rats was not statistically different from the untreated diabetic rat, although changes in kidney endothelin and albumin excretion were observed. 29 These differences might result from the lower dose of enalapril used in their study and the shorter duration of enalapril administration. Losartan led to increased levels of plasma Ang II, due to the activation of the negative feedback system between Ang II and renin activity. However, the decreased kidney hypertrophy seen with losartan may be due to lower intrarenal Ang II. Navar et al. reported that intrarenal Ang II was found to be decreased in Ang II-infused rats treated with losartan. 30 In addition, renal tissue Ang II was significantly reduced in rats on a lowsalt diet treated with either captopril, losartan or the combination of both, irrespective of plasma levels of Ang II. 21 It is of note that the combination group had a lower tissue Ang II than either of the single drug treatment groups. 21 In previous studies, we suggested an increased systemic RAS activity in diabetes in the face of low or normal renin activity. Serum ACE activity is increased in the untreated diabetic rat 18 and in the untreated diabetic rat during pregnancy and postpartum followed by elevated plasma Ang II levels. 31 In the present study, serum ACE in the untreated diabetic rat increased gradually with time, being 22% and 50% greater than in controls after 30 and 60 days, respectively, substantiating our earlier observations. 18 As expected, treatment with enalapril 20 mg/kg almost completely inhibited serum ACE activity. We and others have shown, in humans and rats, that when serum ACE was inhibited by over 90%, kidney cortex ACE activity was inhibited almost completely as well. 32, 33 However, it is of note that losartan administration for 60 days prevented the increase in the enzyme activity seen in the untreated diabetic rats. Similar inhibition of serum ACE activity was observed in the pregnant diabetic rat and was also demonstrated in an in vitro setting. 6 Goetz and Holtz reported that losartan administered to hypertensive rats caused a 40% decrease in aortic ACE activity. 34 The in vitro inhibitory effect of losartan on serum ACE activity is confirmed in this study too.This inhibitory effect is not due to chelating of zinc atoms present in the catalytic sites of ACE, as the presence of Ca ++ at a high concentration did not reduce the inhibition. The losartan doses used in the rats studies are several times greater than those given to human subjects, and the volume of distribution is smaller in rats, therefore the circulating concentration of losartan in rats is probably very high, leading to a significant in vivo inhibition of serum ACE activity. These observations support our previous suggestion that losartan binds directly to the enzyme. 6 This may result in a change in enzyme conformation or may compete with the substrate on binding to the enzyme. Soluble ACE originates predominantly from lung and endothelial cells. The highly significant correlation between serum ACE activity and blood glucose levels support the notion that the release of membranous ACE into the blood, by an unknown mechanism, is triggered by blood glucose levels.This is in agreement with our findings that serum ACE activity was correlated with glycosylated haemoglobin in Type 1 diabetic patients and it explained 15% of the ACE variation. 35 TGF-β 1 is considered to be one of the major cytokines involved in the regulation of extracellular matrix synthesis and degradation. 10, 24 Up-regulation of TGF-β 1 plays a crucial role in the pathogenesis of mesangial matrix expansion in diabetic rats.Among the mechanisms proposed for this upregulation is activation of PKC by hyperglycaemia which has been shown to stimulate TGF-β 1 , together with increased Ang II in cultured mesangial cells. 24 In the present study, plasma TGF-β 1 correlated with urinary protein excretion. Both losartan and enalapril prevented the increase in plasma TGF-β 1 levels seen in the untreated diabetic rat. Similar results were reported in humans and experimental diabetic animals. Sharma et al. 36 reported that administration of captopril to diabetic patients reduced serum TGF-β 1 levels in these patients.This reduction in circulating TGF-β 1 levels was closely correlated with the prevention of progression of diabetic nephropathy. In animal studies, treatment with ACE-Is or ARBs reduced the enhanced TGF-β 1 ‚ expression in the glomerulus. 37 Recently, Volpini et al. showed that the increased urinary TGF-β 1 excretion in untreated diabetic rats was attenuated by enalapril or losartan. 15 The amount of urinary TGF-β 1 excretion was higher in the group of untreated diabetic rats that showed more alterations in albuminuria and GFR, and increased immunohistochemical staining for TGFβ 1 and fibronectin. In addition, a positive correlation between urinary TGF-β 1 excretion and the glomerular area and the fractional mesangial area in the diabetic rats was observed. 15 Recently, combined treatment with lisinopril and anti TGF-β 1 antibodies in STZ diabetic rats ameliorated proteinuria, concomitantly with a reduction in mesangial volume and interstitial pathology in those rats. 17 In summary, interruption of the RAS reduced proteinuria and kidney hypertrophy in the STZ diabetic rat. This was associated with reduced plasma TGF-β 1 levels. STZ-induced diabetes was associated with a progressive rise in serum ACE activity, which was suppressed in losartan-treated rats. The co-administration of losartan and enalapril was associated with an earlier prevention of proteinuria than the administration of each of the compounds alone. Further studies are needed to evaluate the role of TGF-β 1 and ACE in diabetic nephropathy. 
